[Clinical evaluation of effects from neoadjuvant chemotherapy with @entity1259 plus @entity1311 in cases of locally advanced XXXX --comparative study of treatment with 2 and 4 cycles].

@entity1 @entity4444 @entity3933 @entity137 @entity3974 @entity0 @entity1665 @entity5 @entity1259 @entity1311 @entity1902 @entity619 @entity56 @entity1431 @entity4841 @entity925 @entity2359
Neoadjuvant chemotherapy of @entity1259 plus @entity1311 was administered to 75 @entity1 (including a 2-cycle group of 39 @entity1 and a 4-cycle group of 36 @entity1 ) with locally advanced @entity0 (35 cases of stage IIb, 28 of stage IIIa, 12 of stage IIIb) to compare efficacy and @entity137 of 2 cycle and 4 cycle regimens. All @entity1 were female. They were treated with @entity1259 60 mg/m2, on day 1, by i.v., followed by @entity1311 150 mg/m2, by 3 hour continuous infusion on day 2 repeated every 3 weeks. Premedication with @entity619 , @entity3974 , @entity3933 and @entity4444 were administered to prevent gastroenteritic and @entity56 before chemotherapy. Thirty-nine @entity1 were given 2 cycles and thirty-six were given 4 cycles of this regimen. One of 39 @entity1 had complete response, 28 had partial response and 10 had no change in the 2-cycle group. In addition, 21 of 36 @entity1 had complete response (including 9 who had pathologic complete response), 13 had partial response and 2 had no change. The response rates were 74% (29/39) in the 2-cycle group and 94% (34/36) in the 4-cycle group. There were no progressive disease in these 2 groups. However a higher proportion of PR was observed in stage II @entity1 than in stage III @entity1 . Twelve of 36 @entity1 underwent breast conserving surgery, as @entity5 size had become smaller and down-staging was realized after neoadjuvant chemotherapy. In addition, axillary lymph nodes were palpable in all 75 @entity1 before neoadjuvant chemotherapy with the ET regimen. But 46% (18/39) in the 2-cycle group and 75% (27/36) in the 4-cycle group became impalpable. Conversely, major @entity137 (including @entity1431 and @entity1902 ) were similar in both groups, but @entity925 , @entity4841 , @entity2359 and @entity1665 were more severe in the 4-cycle group than in the 2-cycle group. In the present study, neoadjuvant chemotherapy with a 4-cycle ET regimen was more effective than with a 2-cycle regimen in down staging locally advanced @entity0 . Although major @entity137 were more severe in the 4-cycle group than in the 2-cycle group, the regimen was tolerable and safe.
